Taro Pharmaceutical Industries Ltd
F:TAL

Watchlist Manager
Taro Pharmaceutical Industries Ltd Logo
Taro Pharmaceutical Industries Ltd
F:TAL
Watchlist
Price: 40 EUR 1.01% Market Closed
Market Cap: 1.5B EUR

Net Margin
Taro Pharmaceutical Industries Ltd

8.6%
Current
1%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
8.6%
=
Net Income
53.9m
/
Revenue
629.2m

Net Margin Across Competitors

No Stocks Found

Taro Pharmaceutical Industries Ltd
Glance View

Market Cap
1.5B EUR
Industry
Pharmaceuticals

In the often-underappreciated realm of generic pharmaceuticals, Taro Pharmaceutical Industries Ltd. has carved out a notable niche for itself. Founded in 1950 in Haifa, Israel, Taro's journey began with a focus on dermatological products, a specialism that continues to be at the heart of its operations. As generic drug prices have become increasingly competitive, Taro has distinguished itself through a robust portfolio that not only includes dermatology but also topical and oral medications across various therapeutic areas. The company's commitment to quality and cost-effective drug solutions stems from its strategic use of rigorous R&D efforts, channeling years of scientific expertise to bring affordable healthcare solutions to markets worldwide. In essence, Taro crafts a business model that balances operational efficiency with the nuanced complexities of pharmaceutical manufacturing and compliance. Underpinning Taro's business strategy is its prowess in generic drug manufacture, where it maximizes its revenue by capitalizing on patent expirations from mainstream pharmaceutical enterprises. With its deep understanding of regulatory frameworks and market dynamics, Taro adeptly navigates the intricate landscapes of the U.S. and international markets, leveraging its wide distribution network. The United States, being a major revenue driver, reflects Taro's prowess and its ability to quickly adapt to drug lifecycle shifts. Yet, Taro's success isn't solely attributed to scale but also to its meticulous cost management and operational synergies across its global facilities. This orchestration allows it to maintain competitive pricing while ensuring high-quality standards - a testament to its deep-rooted industry experience and strategic foresight.

TAL Intrinsic Value
Not Available
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
8.6%
=
Net Income
53.9m
/
Revenue
629.2m
What is the Net Margin of Taro Pharmaceutical Industries Ltd?

Based on Taro Pharmaceutical Industries Ltd's most recent financial statements, the company has Net Margin of 8.6%.

Back to Top